Search results | asthma

Reports

Asthma Partnering

The Asthma Partnering provides understanding and access to the asthma partnering deals and agreements entered into by the worlds leading healthcare companies

Idiopathic Pulmonary Fibrosis Partnering

The Idiopathic Pulmonary Fibrosis Partnering report provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Osteoporosis Partnering

The Osteoporosis Partnering report provides understanding and access to the osteoporosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Osteoarthritis Partnering

The Osteoarthritis Partnering report provides understanding and access to the osteoarthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

Musculoskeletal Symptoms Partnering

The Musculoskeletal Symptoms Partnering report provides understanding and access to the musculoskeletal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

Muscular Dystrophy Partnering

The Muscular Dystrophy Partnering report provides understanding and access to the muscular dystrophy partnering deals and agreements entered into by the worlds leading healthcare companies.

Bone Fracture Partnering

The Bone Fracture Partnering report provides understanding and access to the bone fracture partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Synairgen in hunt for pharma partners to develop asthma drug

Synairgen Plc  is in talks with potential pharma partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said.

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.

Menarini

Menarini is a top pharmaceutical company based in Florence, Italy

Healthcare M&A trends of 2013 so far

The healthcare sector in 2013 continues to adjust to a new environment of sluggish economic growth, budget constraints, reimbursement challenges, higher regulatory hurdles, and the uncertainties surrounding healthcare reform. Just recently, the European Parliament recently approved, by an overwhelming margin, a tightening up of CE-mark pre-market authorizations and post-mark surveillance of medical devices

Menarini – Dominating the Italian pharmaceutical scene

Menarini or Menarini Group as it is widely known is a large global pharmaceutical company developing treatments for a number of diseases including cardiovascular, gastrointestinal and pain/inflammation.

Partnering with Boehringer Ingelheim: Looking for new opportunities

Boehringer Ingelheim is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Array BioPharma: Company profile

Array BioPharma, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Partnering with Johnson & Johnson / Janssen: Partnering for a healthier future

Johnson & Johnson is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals, medical devices and diagnostics

Menarini: Company Profile

Menarini, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Partnering with AstraZeneca: Partnering for a healthier future

AstraZeneca is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals

Events

Sorry, your search returned no results.


Deals

Janssen and Vectura partner for anti-inflammatory therapies for asthma/COPD

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD

Synairgen in hunt for pharma partners to develop asthma drug

Synairgen Plc  is in talks with potential pharma partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said.

GSK & Five Prime in asthma and COPD drug discovery biotech partnering pact

Five Prime Therapeutics announced that it has entered into its second strategic drug discovery biotech partnering alliance with GlaxoSmithKline GSK +0.61% within two years

Astellas to co-promote AstraZeneca asthma drug in Japan

Astellas, which will be responsible for distribution, will pay AstraZeneca 3.0 billion yen ($31.55 million) upfront in addition to milestone payments of up to 5.5 billion yen, depending on the medicine’s progress in the Japanese market.

MAP Pharmaceuticals announces termination of AstraZeneca pediatric asthma collaboration

The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company.

La Jolla Institute for Allergy and Immunology in exclusive license deal with MedImmune on Aasthma discovery

MedImmune was granted exclusive intellectual property rights to the discovery, which demonstrated the pivotal role of a protein called the OX40 ligand in asthma.

AstraZeneca signs pharma licensing with Synairgen

AstraZeneca announced a global licence agreement with Synairgen for SNG001.

GSK makes a settlement of $105 million

GSK agreed to pay $105 million to settle charges in California, New York, Texas and more than 40 other states that it illegally promoted its asthma drug Advair and antidepressants Wellbutrin and Paxil.

Collaboration agreement for INV102 (nadolol) and INV104 (zafirlukast)

Invion announce a collaboration with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise.

Respiratory R&D collaboration announced for Stallergenes and DBV Technologies

Stallergenes S.A. (Paris:GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin(R) for the treatment of allergies, announced today that they have entered into a research and development agreement for the treatment of birch allergy.